The AHA Friday urged the National Academies of Sciences, Engineering and Medicine to adopt a unified set of guidelines to account for the variables associated with all issues of the eventual allocation of COVID-19 vaccine allocation.

In an effort to ensure the process remains equitable, AHA stressed the importance of a singular message to the public and other stakeholders.

“The country has been confused by the multiple and sometimes conflicting information on testing, infection prevention, return-to-work and school and many other decision points as we move through this pandemic,” AHA wrote. “We recognize that science is evolving, but in this extremely important consideration of achieving immunity, we cannot further the uncertainty of individuals, providers or public health officials.”

Read AHA’s full comments, which also address vaccine hesitancy, the potential for multiple available vaccines, comorbidity considerations and public- and private-sector decisions and policies.

Related News Articles

Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…
Headline
Flu cases are growing or likely growing in 39 states, according to the latest Centers for Disease Control and Prevention data from Nov. 11. COVID-19…
Headline
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
A study published Oct. 30 by the American Heart Association found that people have an elevated risk of heart attack and stroke following flu and COVID-19…